Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort
ConclusionThe evaluation of the proposed classification in a cohort without neoadjuvant treatment did not justify an additional medical borderline subgroup. A new subgroup based on prognostic borderline patients might be the main target group for neoadjuvant protocols in future.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Anatomy | Borderline Tumor | Cancer | Cancer & Oncology | Databases & Libraries | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Statistics | Study | Surgery